Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 187
Filter
1.
Int J Cancer ; 154(8): 1492-1503, 2024 Apr 15.
Article in English | MEDLINE | ID: mdl-37971144

ABSTRACT

Salivary glands have essential roles in maintaining oral health, mastication, taste and speech, by secreting saliva. Salivary glands are composed of several types of cells, and each cell type is predicted to be involved in the carcinogenesis of different types of cancers including adenoid cystic carcinoma (ACC), acinic cell carcinoma (AciCC), salivary duct carcinoma (SDC), myoepithelial carcinoma (MECA) and other histology. In our study, we performed single nucleus RNA-seq on three human salivary gland samples to clarify the gene expression profile of each complex cellular component of the salivary glands and related these expression patterns to expression found in salivary gland cancers (SGC) to infer cell of origin. By single nucleus RNA-seq, salivary gland cells were stratified into four clusters: acinar cells, ductal cells 1, ductal cells 2 and myoepithelial cells/stromal cells. The localization of each cell group was verified by IHC of each cluster marker gene, and one group of ductal cells was found to represent intercalated ductal cells labeled with HES1. Furthermore, in comparison with SGC RNA-seq data, acinar cell markers were upregulated in AciCC, but downregulated in ACC and ductal cell markers were upregulated in SDC but downregulated in MECA, suggesting that markers of origin are highly expressed in some SGC. Cell type expressions in specific SGC histology are similar to those found in normal salivary gland populations, indicating a potential etiologic relationship.


Subject(s)
Carcinoma, Acinar Cell , Carcinoma, Adenoid Cystic , Carcinoma , Salivary Gland Neoplasms , Humans , Biomarkers, Tumor/genetics , Biomarkers, Tumor/metabolism , Salivary Glands/pathology , Salivary Gland Neoplasms/genetics , Salivary Gland Neoplasms/pathology , Carcinoma, Adenoid Cystic/pathology , Carcinoma/pathology , Carcinoma, Acinar Cell/metabolism , RNA/metabolism
2.
Cancer Sci ; 114(3): 1165-1179, 2023 Mar.
Article in English | MEDLINE | ID: mdl-36382538

ABSTRACT

Acinar cell carcinoma (ACC) of the pancreas is a malignant tumor of the exocrine cell lineage with a poor prognosis. Due to its rare incidence and technical difficulties, few authentic human cell lines are currently available, hampering detailed investigations of ACC. Therefore, we applied the organoid culture technique to various types of specimens, such as bile, biopsy, and resected tumor, obtained from a single ACC patient. Despite the initial propagation, none of these organoids achieved long-term proliferation or tolerated cryopreservation, confirming the challenging nature of establishing ACC cell lines. Nevertheless, the biopsy-derived early passage organoid developed subcutaneous tumors in immunodeficient mice. The xenograft tumor histologically resembled the original tumor and gave rise to infinitely propagating organoids with solid features and high levels of trypsin secretion. Moreover, the organoid stained positive for carboxylic ester hydrolase, a specific ACC marker, but negative for the duct cell marker CD133 and the endocrine lineage marker synaptophysin. Hence, we concluded the derivation of a novel ACC cell line of the pure exocrine lineage, designated HS-1. Genomic analysis revealed extensive copy number alterations and mutations in EP400 in the original tumor, which were enriched in primary organoids. HS-1 displayed homozygous deletion of CDKN2A, which might underlie xenograft formation from organoids. Although resistant to standard cytotoxic agents, the cell line was highly sensitive to the proteasome inhibitor bortezomib, as revealed by an in vitro drug screen and in vivo validation. In summary, we document a novel ACC cell line, which could be useful for ACC studies in the future.


Subject(s)
Carcinoma, Acinar Cell , Pancreatic Neoplasms , Humans , Mice , Animals , Carcinoma, Acinar Cell/genetics , Carcinoma, Acinar Cell/metabolism , Carcinoma, Acinar Cell/pathology , Homozygote , Sequence Deletion , Pancreatic Neoplasms/pathology , Organoids/metabolism , Cell Line , Pancreatic Neoplasms
3.
J Oral Pathol Med ; 52(3): 255-262, 2023 Mar.
Article in English | MEDLINE | ID: mdl-36207812

ABSTRACT

BACKGROUND: Secretory carcinoma (SC) is a well-established salivary gland malignancy that has earned its popularity for its unique clinicopathological behavior. Although it is an indolent malignancy, few of them have been reported with high grade transformation making it mandatory to differentiate it from its prime histological mimicker, acinic cell carcinoma (AciCC). Recently, many studies have been directed toward validating the sensitivity and specificity of pan-TRK IHC for confirming ETV6::NTRK3 gene fusion in SCs involving salivary gland. AIM: The aim of the present systematic review was to establish the diagnostic utility of pan-TRK immunostaining in histological differentiation of SC from AciCC. MATERIAL AND METHODS: An electronic search was carried out using MEDLINE by PubMed, Scopus, Google scholar, Trip, Cochrane library and EMBASE databases. Articles in which SC assessed with pan-TRK immunohistochemical expressions were included for systematic review and their staining pattern (cytoplasmic, nuclear and/or combined), sensitivity, specificity, positive as well as negative predictive were gathered. Risk of bias was analyzed for each study using QUADAS-2 tool. RESULTS: Thirteen eligible articles were included for the quantitative analysis, which revealed positive immunostaining of pan-TRK by nearly all the ETV6::NTRK3 fusion prevalent SCs alongside negative expression in almost all the cases of AciCC with 100% of sensitivity as well as specificity. CONCLUSION: The evidence from the included studies supports that pan-TRK immunostaining could be used as a reliable preliminary screening tool for discerning SC from AciCC. PROSPERO No: CRD42022308913.


Subject(s)
Breast Neoplasms , Carcinoma, Acinar Cell , Carcinoma , Salivary Gland Neoplasms , Humans , Female , Immunohistochemistry , Carcinoma, Acinar Cell/diagnosis , Carcinoma, Acinar Cell/genetics , Carcinoma, Acinar Cell/metabolism , Biomarkers, Tumor/metabolism , Salivary Glands/metabolism , Breast Neoplasms/pathology , Salivary Gland Neoplasms/pathology , Carcinoma/genetics
4.
Cytopathology ; 34(3): 219-224, 2023 05.
Article in English | MEDLINE | ID: mdl-36825365

ABSTRACT

OBJECTIVES: Acinic cell carcinoma (AcCC) is often a challenging diagnosis on cytology. Recently, NOR-1 (NR4A3) has been demonstrated as a sensitive and specific marker for AcCC. Therefore, we conducted this study to evaluate NOR-1 expression in AcCC cytology specimens and to compare its reactivity in other salivary gland tumours (non-AcCC). METHODS: We retrospectively reviewed our database and selected cytology cases with available cell blocks, including 10 AcCC and 24 non-AcCC tumours (12 benign tumours and 12 malignant tumours). NOR-1 (1:50 dilution; SC393902 [H-7]; Santa Cruz Biotech) immunohistochemistry (IHC) was performed on all cases. RESULTS: All AcCC cases except two (2/10, 80%) showed positive nuclear staining of variable intensity for NOR-1, with the majority of cases (75%) demonstrating at least moderately intense nuclear expression. All non-AcCC cases were negative for NOR-1, demonstrating a specificity of 100%. CONCLUSION: We conclude that NOR-1 IHC is sensitive and very specific on cytology specimens and is able to distinguish AcCC from its mimickers reliably and classify them appropriately for further management.


Subject(s)
Carcinoma, Acinar Cell , Receptors, Steroid , Salivary Gland Neoplasms , Humans , Carcinoma, Acinar Cell/diagnosis , Carcinoma, Acinar Cell/metabolism , Carcinoma, Acinar Cell/pathology , Immunohistochemistry , Retrospective Studies , Biomarkers, Tumor/metabolism , Salivary Glands/pathology , Salivary Gland Neoplasms/diagnosis , Salivary Gland Neoplasms/pathology , DNA-Binding Proteins/metabolism , Receptors, Steroid/metabolism , Receptors, Thyroid Hormone/metabolism
5.
Proc Natl Acad Sci U S A ; 116(14): 6790-6799, 2019 04 02.
Article in English | MEDLINE | ID: mdl-30894480

ABSTRACT

While cells within tissues generate and sense 3D states of strain, the current understanding of the mechanics of fibrous extracellular matrices (ECMs) stems mainly from uniaxial, biaxial, and shear tests. Here, we demonstrate that the multiaxial deformations of fiber networks in 3D cannot be inferred solely based on these tests. The interdependence of the three principal strains gives rise to anomalous ratios of biaxial to uniaxial stiffness between 8 and 9 and apparent Poisson's ratios larger than 1. These observations are explained using a microstructural network model and a coarse-grained constitutive framework that predicts the network Poisson effect and stress-strain responses in uniaxial, biaxial, and triaxial modes of deformation as a function of the microstructural properties of the network, including fiber mechanics and pore size of the network. Using this theoretical approach, we found that accounting for the Poisson effect leads to a 100-fold increase in the perceived elastic stiffness of thin collagen samples in extension tests, reconciling the seemingly disparate measurements of the stiffness of collagen networks using different methods. We applied our framework to study the formation of fiber tracts induced by cellular forces. In vitro experiments with low-density networks showed that the anomalous Poisson effect facilitates higher densification of fibrous tracts, associated with the invasion of cancerous acinar cells. The approach developed here can be used to model the evolving mechanics of ECM during cancer invasion and fibrosis.


Subject(s)
Carcinoma, Acinar Cell , Collagen , Extracellular Matrix , Models, Molecular , Neoplasm Proteins , Animals , Carcinoma, Acinar Cell/chemistry , Carcinoma, Acinar Cell/metabolism , Carcinoma, Acinar Cell/pathology , Cell Line, Tumor , Collagen/chemistry , Collagen/metabolism , Extracellular Matrix/chemistry , Extracellular Matrix/metabolism , Humans , Neoplasm Proteins/chemistry , Neoplasm Proteins/metabolism , Rats
6.
Int J Cancer ; 146(9): 2619-2627, 2020 05 01.
Article in English | MEDLINE | ID: mdl-31509606

ABSTRACT

Neuropilin-2 (NRP2) is a member of the neuropilin receptor family and known to regulate autophagy and mTORC2 signaling in prostate cancer (PCa). Our study investigated the association of immunohistochemical NRP2 expression with clinicopathological data in PCa patients. For this purpose, we generated a tissue microarray with prostate tissue specimens from 400 PCa patients treated by radical prostatectomy. We focused on patients with high-risk factors such as extraprostatic extension (pT ≥ 3), Gleason score ≥8 and/or the presence of regional lymph node metastases (pN1). Protein levels of NRP2, the vascular endothelial growth factor C (VEGFC) and oncogenic v-ets avian erythroblastosis virus E26 oncogene homolog (ERG) gene as an indicator for TMPRSS2-ERG fusion was assessed in relation to the patients' outcome. NRP2 emerged as an independent prognostic factor for cancer-specific survival (CSS) (hazard ratio 2.360, 95% confidence interval = 1.2-4.8; p = 0.016). Moreover, the association between NRP2 expression and shorter CSS was also especially pronounced in patients at high risk for progression (log-rank test: p = 0.010). We evaluated the association between NRP2 and the TMPRSS2-ERG gene fusion status assessed by immunohistochemical nuclear ERG staining. However, ERG staining alone did not show any prognostic significance. NRP2 immunostaining is significantly associated with shorter CSS in ERG-negative tumors (log-rank test: p = 0.012). No prognostic impact of NRP2 expression on CSS was observed in ERG-positive tumors (log-rank test: p = 0.153). Our study identifies NRP2 as an important prognostic marker for a worse clinical outcome especially in patients with a high-risk PCa and in patients with ERG-negative PCa.


Subject(s)
Biomarkers, Tumor/metabolism , Carcinoma, Acinar Cell/mortality , Neuropilin-2/metabolism , Prostatic Neoplasms/mortality , Serine Endopeptidases/metabolism , Aged , Biomarkers, Tumor/genetics , Carcinoma, Acinar Cell/metabolism , Carcinoma, Acinar Cell/pathology , Carcinoma, Acinar Cell/surgery , Case-Control Studies , Cohort Studies , Disease Progression , Follow-Up Studies , Gene Expression Regulation, Neoplastic , Humans , Male , Neuropilin-2/genetics , Prognosis , Prostatic Neoplasms/metabolism , Prostatic Neoplasms/pathology , Prostatic Neoplasms/surgery , Serine Endopeptidases/genetics , Survival Rate
7.
Histopathology ; 75(1): 54-62, 2019 Jul.
Article in English | MEDLINE | ID: mdl-30801752

ABSTRACT

AIMS: Secretory carcinoma (previously known as mammary analogue secretory carcinoma) is characterised by ETV6 rearrangements, most often ETV6-NTRK3 fusion. Given its histological overlap with other salivary gland tumours, secretory carcinoma can be difficult to diagnose without genetic confirmation. A recently developed pan-TRK antibody shows promise for identifying tumours with NTRK fusions. The aim of this study was to evaluate the utility of pan-TRK immunohistochemistry in distinguishing secretory carcinoma from mimics. METHODS AND RESULTS: We examined whole-tissue sections from 86 tumours, including 14 secretory carcinomas (12 parotid primaries and one buccal primary, and one metastasis; five with ETV6 rearrangement confirmed by fluorescence in-situ hybridisation, and one with ETV6-NTRK3 fusion and one with ETV6-RET fusion detected by targeted sequencing), 14 acinic cell carcinomas, 18 polymorphous adenocarcinomas, 20 low-grade mucoepidermoid carcinomas, and 20 pleomorphic adenomas. Immunohistochemistry was performed with a pan-TRK rabbit monoclonal antibody. Pan-TRK staining was detected in nine (64%) secretory carcinomas, all with a nuclear pattern and four with diffuse staining (>50% of cells). Among other tumour types, pan-TRK immunoreactivity was observed in all (100%) pleomorphic adenomas (particularly myoepithelial cell-rich, myxoid areas), 15 (83%) polymorphous adenocarcinomas, and four (20%) low-grade mucoepidermoid carcinomas, all with predominantly membranous/cytoplasmic immunoreactivity; only six cases showed focal (<10%) nuclear staining. All acinic cell carcinomas were entirely negative. CONCLUSIONS: Although pan-TRK expression is not entirely sensitive or specific for secretory carcinoma, nuclear staining distinguishes secretory carcinoma from mimics. Acinic cell carcinomas are negative for pan-TRK, though membranous expression of TRK is common in other salivary gland neoplasms. The lack of pan-TRK immunoreactivity in a subset of secretory carcinomas may suggest non-NTRK fusion partners.


Subject(s)
Carcinoma, Acinar Cell/metabolism , Carcinoma, Acinar Cell/pathology , Receptor Protein-Tyrosine Kinases/metabolism , Salivary Gland Neoplasms/metabolism , Salivary Gland Neoplasms/pathology , Adult , Aged , Antibodies, Monoclonal , Carcinoma, Acinar Cell/genetics , Diagnosis, Differential , Female , Gene Fusion , Humans , Immunohistochemistry , Male , Middle Aged , Oncogene Proteins, Fusion/genetics , Proto-Oncogene Proteins c-ets/genetics , Proto-Oncogene Proteins c-ret/genetics , Receptor Protein-Tyrosine Kinases/genetics , Receptor Protein-Tyrosine Kinases/immunology , Repressor Proteins/genetics , Salivary Gland Neoplasms/genetics , Young Adult , ETS Translocation Variant 6 Protein
8.
J Biol Regul Homeost Agents ; 33(2): 563-569, 2019.
Article in English | MEDLINE | ID: mdl-30916513

ABSTRACT

This study aimed to detect the expression of Mucin 1 (MUC1) in acinic cell carcinoma (AciCC) of salivary gland and to explore the relationship between MUC1 and clinicopathological factors of AciCC of salivary gland. Patients with salivary gland tumors who were treated at our hospital were enrolled in this study. The pathological sections collected from all subjects were classified by histological examinations. In addition, 40 cases of primary salivary gland AciCC tissues were selected and classified into experimental group, whereas 40 cases of normal salivary gland (NSG) tissues were selected and classified into control group. MUC1 positive cells in both experimental and control groups were detected by immunohistochemistry assays, while all clinical data were analyzed statistically. The results showed that MUC1 was only expressed in the ductal epithelium of NSG and distributed at the apical side of the cell membrane. In primary salivary gland AciCC tissues, scattered expressions of MUC1 were found both on the cell membrane and in the cytoplasm of tumor cells, and sometimes even in the cell nuclei, thus completely eliminating the polarized distribution of MUC1 expressions. The percentage of MUC1 positive cells in experimental group was significantly higher than that in control group (P < 0.05). In addition, the expression of MUC1 in salivary gland AciCC was correlated with gender, age, histological type, lesion location, cervical lymph node metastasis, local recurrence, and distant metastasis. In conclusion, MUC1 is related to the occurrence and development of salivary gland AciCC. Therefore, MUC1 may be used as a novel tumor marker in the clinical diagnosis and treatment of salivary gland AciCC.


Subject(s)
Carcinoma, Acinar Cell/metabolism , Mucin-1/metabolism , Salivary Gland Neoplasms/metabolism , Biomarkers, Tumor/metabolism , Carcinoma, Acinar Cell/pathology , Humans , Immunohistochemistry , Lymphatic Metastasis , Neoplasm Recurrence, Local , Salivary Gland Neoplasms/pathology
9.
Eur Arch Otorhinolaryngol ; 276(12): 3461-3466, 2019 Dec.
Article in English | MEDLINE | ID: mdl-31440815

ABSTRACT

PURPOSE: Mammary analogue secretory carcinoma (SC) of the parotid gland is a relatively uncommon cancer associated with the ETV6-NTRK3 fusion product similar to breast cancer. The clinical characteristics and outcome of treatment were reviewed for patients with this tumor at our hospital. METHODS: In this retrospective case series, 24 patients with a diagnosis of acinic cell carcinoma (AcCC) of the parotid gland were classified as having either SC or AcCC based on analysis of the ETV6-NTRK3 fusion gene. These two groups were compared with respect to their clinical and imaging characteristics (MRI/US), cytologic findings, accuracy of fine-needle aspiration cytology and frozen section, treatment outcomes, and immunohistochemical findings. RESULTS: Based on re-classification by ETV6-NTRK3 fusion gene analysis, the diagnosis was SC in 14 patients and AcCC in 10 patients. The SC group had a significantly higher proportion of male patients and was also significantly younger than the AcCC group. Imaging studies revealed that SC was significantly more likely to show internal heterogeneity. Correct grading of both tumors was comparable by fine needle aspiration, with the rate being 60% for AcCC and 50% for SC. Diagnosis by frozen section biopsy diagnosis obtained the correct grade in 90% of the AcCC group and 93% of the SC group. CONCLUSIONS: In 24 patients previously diagnosed with AcCC, re-analysis of the ETV6-NTRK3 fusion product indicated that 14 patients actually had SC. Although AcCC and SC show similarities of their biological aggressiveness and prognosis, patients with SC were significantly more likely to be male and younger.


Subject(s)
Carcinoma, Acinar Cell/genetics , Carcinoma, Acinar Cell/pathology , Immunohistochemistry/methods , Parotid Gland/pathology , Parotid Neoplasms/genetics , Parotid Neoplasms/pathology , Adult , Biomarkers, Tumor/metabolism , Biopsy, Fine-Needle , Carcinoma, Acinar Cell/metabolism , Female , Humans , Male , Middle Aged , Oncogene Proteins, Fusion/genetics , Oncogene Proteins, Fusion/metabolism , Parotid Neoplasms/metabolism , Prognosis , Retrospective Studies
11.
Zhonghua Bing Li Xue Za Zhi ; 47(4): 274-278, 2018 Apr 08.
Article in Zh | MEDLINE | ID: mdl-29690667

ABSTRACT

Objective: To investigate clinical, pathological and immunohistochemical features of pancreatic acinar cell carcinoma. Methods: A retrospective review of surgical and pathological databases between 2011 and 2016 at PLA General Hospital was collected and 14 cases of acinar cell carcinoma (ACC) of the pancreas were identified. EnVision immunohistochemistry was used to detect the expression of Trypsin, bcl-10 and cytokeratin(CK) proteins. Results: The patients included nine cases of pure ACC, 3 cases of mixed acinar ductal carcinoma, 1 case of mixed acinar-neuroendocrine carcinoma and acinar-ductal-neuroendocrine carcinoma, respectively. Tumors involved different anatomic locations of the pancreas, including eight involving the head of pancreas, four in the body and tail, one in the uncinate process and one in a heterotopic pancreas. Two patients had lymph node and liver metastases before surgery. Microscopically, the tumor was hypercellular with less fibroblastic proliferation and tumor cells arranged in acinar or solid pattern. The well differentiated tumor cells showed eosinophilic, granular cytoplasm with single prominent nucleoli, while the poorly differentiated tumor cells tended to grow in solid sheets. Immunohistochemically, the tumor cells were positive for pan-cytokeratin (14/14), Trypsin (12/14) and bcl-10 (11/14). Stains for CK7 and CK19 were negative (11/14 and 3/4). According to the pTNM staging, there were 7 cases at stageⅠ, 3 at stage ⅡA, 3 at stage Ⅲ and 1 at stage Ⅳ. With average postoperative follow-up of 6-58 months, the median disease-free survival time was 16 months. Conclusions: Pancreatic acinar cell carcinoma is a rare and relatively indolent malignant tumor with characteristic histopathological and immunohistochemical features. Accurate pathological diagnosis plays an important role in patients' treatment and evaluation of prognosis.


Subject(s)
Carcinoma, Acinar Cell/pathology , Carcinoma, Neuroendocrine/pathology , Pancreatic Neoplasms/pathology , Carcinoma, Acinar Cell/metabolism , Carcinoma, Neuroendocrine/metabolism , Cell Proliferation , Disease-Free Survival , Humans , Immunohistochemistry , Keratins/metabolism , Pancreas/pathology , Pancreatic Neoplasms/metabolism , Prognosis , Retrospective Studies , Pancreatic Neoplasms
12.
Breast Cancer Res ; 19(1): 68, 2017 06 07.
Article in English | MEDLINE | ID: mdl-28592291

ABSTRACT

BACKGROUND: Myocardin-related transcription factors (MRTF) A and B link actin dynamics and mechanotransduction to gene expression. In mice, MRTF-A is involved in mammary gland differentiation, but its role in human mammary epithelial cells remains unclear. METHODS: Three-dimensional cultures of human mammary epithelial MCF10A cells were used to model acinar morphogenesis. Stable MRTF-A knockdown, MRTF-A/B rescue and MRTF-A/B overexpression was established to characterize the functional role during morphogenesis using confocal microscopy and expression analysis. Breast cancer patient databases were analyzed for MRTF-A expression. RESULTS: We showed that a precise temporal control of MRTFs is required for normal morphogenesis of MCF10A mammary acini. MRTF transcriptional activity, but not their protein amounts, is transiently induced during 3D acini formation. MRTF-A knockdown dramatically reduces acini size and prevents lumen formation. These effects are rescued by re-expression of MRTF-A, and partially by MRTF-B. Conversely, overexpression of MRTF-A and MRTF-B increases acini size, resulting in irregular spheroids without lumen and defective apico-basal polarity. These phenotypes correlate with deregulated expression of cell cycle inhibitors p21/Waf1, p27/Kip1 and altered phosphorylation of retinoblastoma protein. In MRTF overexpressing spheroids, proliferation and apoptosis are simultaneously increased at late stages, whilst neither occurs in control acini. MRTFs interfere with anoikis of the inner cells and cause an integrin switch from α6 to α5, repression of E-cadherin and induction of mesenchymal markers vimentin, Snai2 and Zeb1. Moreover, MRTF-overexpressing spheroids are insensitive to alteration in matrix stiffness. In two breast cancer cohorts, high expression of MRTF-A and known target genes was associated with decreased patient survival. CONCLUSION: MRTF-A is required for proliferation and formation of mammary acini from luminal epithelial cells. Conversely, elevated MRTF activity results in pre-malignant spheroid formation due to defective proliferation, polarity loss and epithelial-mesenchymal transition.


Subject(s)
Acinar Cells/metabolism , Epithelial-Mesenchymal Transition , Epithelium/metabolism , Trans-Activators/metabolism , Acinar Cells/pathology , Breast Neoplasms/genetics , Breast Neoplasms/metabolism , Breast Neoplasms/mortality , Breast Neoplasms/pathology , Carcinoma, Acinar Cell/genetics , Carcinoma, Acinar Cell/metabolism , Carcinoma, Acinar Cell/mortality , Carcinoma, Acinar Cell/pathology , Cell Cycle/genetics , Cell Line , Cell Transformation, Neoplastic/genetics , Cell Transformation, Neoplastic/metabolism , Epithelial-Mesenchymal Transition/genetics , Epithelium/pathology , Female , Gene Expression , Gene Knockdown Techniques , Genes, Reporter , Humans , Kaplan-Meier Estimate , Prognosis , Promoter Regions, Genetic , Trans-Activators/genetics
13.
Eur Arch Otorhinolaryngol ; 273(11): 3511-3531, 2016 Nov.
Article in English | MEDLINE | ID: mdl-26685679

ABSTRACT

Epidemiologic and clinicopathologic features, therapeutic strategies, and prognosis for acinic cell carcinoma of the major and minor salivary glands are critically reviewed. We explore histopathologic, histochemical, electron microscopic and immunohistochemical aspects and discuss histologic grading, histogenesis, animal models, and genetic events. In the context of possible diagnostic difficulties, the relationship to mammary analog secretory carcinoma is probed and a classification is suggested. Areas of controversy or uncertainty, which may benefit from further investigations, are also highlighted.


Subject(s)
Carcinoma, Acinar Cell , Animals , Carcinoma, Acinar Cell/epidemiology , Carcinoma, Acinar Cell/metabolism , Carcinoma, Acinar Cell/pathology , Carcinoma, Acinar Cell/therapy , Diagnosis, Differential , Disease Models, Animal , Humans , Microscopy, Electron , Parotid Gland , Preoperative Care , Prognosis , Salivary Gland Neoplasms/epidemiology , Salivary Gland Neoplasms/metabolism , Salivary Gland Neoplasms/pathology , Salivary Gland Neoplasms/therapy , Salivary Glands, Minor
14.
Med Mol Morphol ; 49(3): 177-81, 2016 Sep.
Article in English | MEDLINE | ID: mdl-25600280

ABSTRACT

E-cadherin expression patterns in acinar cell carcinomas (ACCs) of the pancreas have not been well documented. Herein, we present a hitherto undescribed case of E-cadherin-negative ACC with a solid pseudopapillary growth pattern in a 65-year-old man. We used an antibody against the extracellular domain of E-cadherin. As a further unusual status in ACC, faint ß-catenin expression was observed in the cytoplasm of carcinoma cells. Morphological distinction from a solid pseudopapillary neoplasm (SPN) of the pancreas might be problematic in such a case, because of their similarities concerned with the growth pattern and E-cadherin negativity. Without nuclear accumulation of ß-catenin, a diagnosis of SPN was almost excluded. Immunoreactivity for trypsin and BCL10 made an accurate diagnosis of ACC to this case. The tumor recurred 10 months post-surgery as rapidly enlarging masses in the liver, presumably indicating the aggressiveness of the E-cadherin-negative phenotype among ACCs.


Subject(s)
Cadherins/metabolism , Carcinoma, Acinar Cell/metabolism , Carcinoma, Acinar Cell/pathology , Carcinoma, Papillary/metabolism , Carcinoma, Papillary/pathology , Pancreatic Neoplasms/metabolism , Pancreatic Neoplasms/pathology , Aged , Antigens, CD , Carcinoma, Acinar Cell/diagnostic imaging , Carcinoma, Papillary/diagnostic imaging , Cell Proliferation , Humans , Immunohistochemistry , Male , Pancreatic Neoplasms/diagnostic imaging
15.
Mol Cancer ; 14: 212, 2015 Dec 18.
Article in English | MEDLINE | ID: mdl-26683340

ABSTRACT

BACKGROUND: Pancreatic acinar cell carcinoma (ACC) is a rare tumor entity with an unfavorable prognosis. Recent whole-exome sequencing identified p53 mutations in a subset of human ACC. Activation of the mammalian target of rapamycin (mTOR) pathway is associated with various pancreatic neoplasms. We thus aimed at analyzing whether activation of mTOR with a concomitant loss of p53 may initiate ACC. METHODS: We generated transgenic mouse models in which mTOR was hyperactivated through pancreas-specific, homozygous tuberous sclerosis 1 (Tsc1) deficiency, with or without deletion of p53 (Tsc1 (-/-) and Tsc1 (-/-) ; p53 (-/-) ). Activity of mTOR signaling was investigated using mouse tissues and isolated murine cell lines. Human ACC specimens were used to corroborate the findings from the transgenic mouse models. RESULTS: Hyperactive mTOR signaling in Tsc1 (-/-) mice was not oncogenic but rather induced a near-complete loss of the pancreatic acinar compartment. Acinar cells were lost as a result of apoptosis which was associated with p53 activation. Concomitantly, ductal cells were enriched. Ablation of p53 in Tsc1-deficient mice prevented acinar cell death but promoted formation of acinar cells with severe nuclear abnormalities. One out of seven Tsc1 (-/-) ; p53 (-/-) animals developed pancreatic tumors showing a distinctive tumor morphology, reminiscent of human ACC. Hyperactive mTOR signaling was also detected in a subset of human ACC. CONCLUSION: Hyperactive mTOR signaling combined with loss of p53 in mice induces tumors similar to human ACC.


Subject(s)
Carcinoma, Acinar Cell/metabolism , Pancreatic Neoplasms/metabolism , TOR Serine-Threonine Kinases/metabolism , Tumor Suppressor Protein p53/genetics , Animals , Apoptosis , Carcinoma, Acinar Cell/genetics , Humans , Mice, Inbred BALB C , Mice, Inbred C57BL , Mice, Nude , Mice, Transgenic , Neoplasm Transplantation , Organ Specificity , Pancreas/metabolism , Pancreas/pathology , Pancreatic Neoplasms/genetics , Signal Transduction , Tuberous Sclerosis Complex 1 Protein , Tumor Suppressor Protein p53/metabolism , Tumor Suppressor Proteins/genetics , Tumor Suppressor Proteins/metabolism
16.
Prostate ; 75(14): 1610-9, 2015 Oct.
Article in English | MEDLINE | ID: mdl-26178158

ABSTRACT

BACKGROUND: Prostatic ductal adenocarcinoma is an unusual and aggressive morphologic subtype of prostate cancer. PTEN gene deletion and ERG gene rearrangement are among the most common genomic changes in acinar prostate cancers. Though ductal adenocarcinoma most commonly occurs with synchronous usual-type acinar adenocarcinoma, little is known about the molecular phenotype of these mixed tumors. METHODS: We used genetically validated immunohistochemistry (IHC) assays to assess PTEN and ERG status in a group of 37 surgically treated ductal adenocarcinomas and 18 synchronous acinar adenocarcinomas where we have previously reported ERG gene rearrangement status by fluorescence in situ hybridization (FISH). A group of 34 stage and grade-matched pure acinar adenocarcinoma cases was studied as a control. RESULTS: ERG IHC was highly concordant with ERG FISH results, with 100% (36/36) concordance among ductal adenocarcinomas and 91% (31/34) concordance among 34 pure acinar carcinomas. Similar to previous FISH results, ERG expression by IHC was significantly less common among ductal adenocarcinomas (11% or 4/37) and their synchronous acinar tumors (6% or 1/18) compared to matched pure acinar adenocarcinoma cases (50% or 17/34; P = 0.0005 and 0.002, respectively). PTEN loss by IHC was also less common among ductal adenocarcinomas (18% or 6/34) and their synchronous acinar tumors (22% or 4/18) compared to matched pure acinar carcinomas (50% or 17/34; P = 0.01 and 0.08, respectively). As expected, PTEN loss was enriched among ERG positive compared to ERG-negative tumors in the pure acinar tumor control group (2.5-fold enrichment; P = 0.04) however this was not observed among the ductal adenocarcinomas (1.5 fold enrichment; P = NS). Of ductal adenocarcinomas with an evaluable synchronous acinar component, ERG status was concordant in 94% (17/18) and PTEN status was concordant in 94% (16/17). CONCLUSIONS: Based on PTEN and ERG, ductal adenocarcinomas and their concurrent acinar carcinomas may be clonally related in some cases and show important molecular differences from pure acinar carcinoma.


Subject(s)
Biomarkers, Tumor/biosynthesis , Carcinoma, Acinar Cell/metabolism , Carcinoma, Ductal/metabolism , PTEN Phosphohydrolase/deficiency , Prostatic Neoplasms/metabolism , Trans-Activators/biosynthesis , Carcinoma, Acinar Cell/pathology , Carcinoma, Ductal/pathology , Gene Expression Regulation, Neoplastic , Humans , Male , Prostatic Neoplasms/pathology , Transcriptional Regulator ERG
17.
Ann Diagn Pathol ; 18(3): 146-50, 2014 Jun.
Article in English | MEDLINE | ID: mdl-24675392

ABSTRACT

The differential diagnosis of solid pseudopapillary neoplasm (SPN) from some other nonductal pancreatic tumors may be difficult because of similarities in morphological features. Therefore, immunohistochemical staining is frequently necessary. α-Methylacyl-CoA racemase (AMACR) is a diagnostically useful marker for prostatic cancer and papillary renal cell carcinoma. The aim of this study was to investigate AMACR as a new immunohistochemical marker to differentiate SPNs from other nonductal pancreatic tumors. We investigated immunohistochemical staining for AMACR in 26 SPNs, 21 pancreatic neuroendocrine tumors, and 7 acinar cell carcinomas. All cases of SPN showed granular cytoplasmic expression of AMACR, whereas all cases of pancreatic neuroendocrine tumors and acinar cell carcinomas were negative for this immunohistochemical marker. Hence, our findings demonstrate for the first time that AMACR is a useful immunohistochemical marker for the differential diagnosis of SPNs.


Subject(s)
Carcinoma, Acinar Cell/diagnosis , Neuroendocrine Tumors/diagnosis , Pancreatic Neoplasms/diagnosis , Racemases and Epimerases/metabolism , Adolescent , Adult , Aged , Biomarkers, Tumor/metabolism , Biopsy , Carcinoma, Acinar Cell/metabolism , Carcinoma, Papillary/diagnosis , Carcinoma, Papillary/metabolism , Diagnosis, Differential , Female , Humans , Immunohistochemistry/methods , Male , Middle Aged , Neuroendocrine Tumors/metabolism , Pancreatic Neoplasms/metabolism , Young Adult , beta Catenin/genetics
18.
Med Mol Morphol ; 47(1): 57-61, 2014 Mar.
Article in English | MEDLINE | ID: mdl-23955668

ABSTRACT

Mammary analogue secretory carcinoma (MASC) is a recently described malignancy of the salivary glands characterized by an ETV6-NTRK3 (EN) fusion gene. Morphologically, MASC is sometimes difficult to distinguish from acinic cell carcinoma. Consequently, identifying the chromosomal translocation is essential for diagnosis. We present a case of parotid gland MASC in a 13-year-old boy. To the best of our knowledge, this is the youngest case reported in the literature. Histologic evaluation showed a tumor composed of microcysts, tubular structures, solid nests, or papillary architecture, with secretions within the lumens of the cysts or tubules. Immunohistochemically, tumor cells showed diffuse positive staining of S-100 protein, cytokeratin 19, and vimentin. ETV6 rearrangement was detected by fluorescence in situ hybridization and EN fusion transcripts were verified by reverse transcription (RT-PCR) assay.


Subject(s)
Parotid Gland/metabolism , Salivary Gland Neoplasms/genetics , Salivary Gland Neoplasms/metabolism , Adolescent , Carcinoma, Acinar Cell/diagnosis , Carcinoma, Acinar Cell/genetics , Carcinoma, Acinar Cell/metabolism , Diagnosis, Differential , Gene Rearrangement , Humans , Immunohistochemistry , In Situ Hybridization, Fluorescence , Keratin-19/metabolism , Male , Oncogene Proteins, Fusion/genetics , Parotid Gland/pathology , Parotid Gland/surgery , Proto-Oncogene Proteins c-ets/genetics , Repressor Proteins/genetics , Reverse Transcriptase Polymerase Chain Reaction , S100 Proteins/metabolism , Salivary Gland Neoplasms/diagnosis , Taiwan , Vimentin/metabolism , ETS Translocation Variant 6 Protein
19.
Zhonghua Bing Li Xue Za Zhi ; 43(4): 251-5, 2014 Apr.
Article in Zh | MEDLINE | ID: mdl-24915816

ABSTRACT

OBJECTIVE: To study the expression, clinicopathologic correlation and prognostic significance of caveolin-1 in lung adenocarcinomas(LAC). METHODS: Immunohistochemical study (EnVision method) for caveolin-1 and TTF-1 was carried out in 185 cases of LAC encountered during the period from 2005 to 2010. The correlation between caveolin-1 expression and various clinicopathologic parameters was analyzed statistically. RESULTS: The rate of caveolin-1 expression in the 185 cases of LAC was 26.5% (49/185) and significantly lower than that in normal lung tissue (P<0.01). There was also higher rate of caveolin-1 expression in male patients (P=0.004), smokers (P=0.006), tumors larger than 3.5 cm (P=0.048), predominantly solid tumor subtype (P=0.025), high tumor grade (P=0.044), tumors with vascular invasion (P=0.019), lymph node metastasis (P=0.030), recurrence (P=0.021) and high clinical stage (P=0.027). The expression level of caveolin-1 in TTF1-negative cases was significantly higher than that in TTF1-positive cases and caveolin-1 expression also negatively correlated with TTF-1 expression in LAC (r=-0.154, P=0.037). The five-year overall survival rate of patients with caveolin-1 positive tumors was lower than that in caveolin-1 negative group (P<0.01).Univariate analysis indicated the expression level of caveolin-1 and TTF-1 (P<0.01), histologic subtype (P=0.002), tumor grade (P=0.002), tumor size (P=0.009), vascular invasion (P=0.019), lymph node metastasis (P=0.018), recurrence (P=0.032) and clinical stage (P=0.024) correlated with the survival of patients with LAC. COX multivariate analysis revealed that LAC with caveolin-1 positive expression, TTF-1 negative expression and high tumor grade carried a significantly unfavorable prognosis. CONCLUSION: Caveolin-1 expression correlates with histologic subtype, tumor grade, invasiveness and metastatic potential of LAC. The detection of caveolin-1 in LAC is helpful in predicting prognosis.LAC with caveolin-1 expression carries a poor prognosis.


Subject(s)
Adenocarcinoma/metabolism , Caveolin 1/metabolism , Lung Neoplasms/metabolism , Adenocarcinoma/pathology , Adenocarcinoma/surgery , Adenocarcinoma of Lung , Adenocarcinoma, Papillary/metabolism , Adenocarcinoma, Papillary/pathology , Adenocarcinoma, Papillary/surgery , Adult , Aged , Aged, 80 and over , Carcinoma, Acinar Cell/metabolism , Carcinoma, Acinar Cell/pathology , Carcinoma, Acinar Cell/surgery , DNA-Binding Proteins/metabolism , Female , Follow-Up Studies , Humans , Lung Neoplasms/pathology , Lung Neoplasms/surgery , Lymphatic Metastasis , Male , Middle Aged , Neoplasm Recurrence, Local , Neoplasm Staging , Prognosis , Survival Rate , Transcription Factors , Tumor Burden
20.
Auris Nasus Larynx ; 51(4): 755-760, 2024 Aug.
Article in English | MEDLINE | ID: mdl-38852332

ABSTRACT

OBJECTIVE: While several studies reported epidermal growth factor receptor (EGFR) expression in salivary gland cancer (SGC), results varied due to a lack of unified definition of EGFR positivity. In this study, we assessed the EGFR expression level using both EGFR positive score and cumulative EGFR score in the patients with SGC. METHODS: Between January 2010 and April 2021, 102 patients with SGC who underwent surgical resection were reviewed retrospectively by immunohistochemistry. The membrane staining intensity was scored as follows: no staining (0), weak staining (1+), intermediate staining (2+), and strong staining (3+). The cumulative EGFR score was determined on a continuous scale of 0-300 using the formula:1 × (1+: percentage of weakly stained cells) + 2 × (2+: percentage of moderately stained cells) + 3 × (3+: percentage of strongly stained cells). RESULTS: EGFR expression in SGC varied widely even among the same as well as different histopathological types. The average EGFR positive scores were 46.0 %, 55.7 %, 51.6 %, 1.0 %, 26.8 %, 50 %, and 76.8 % for mucoepidermoid carcinoma (MEC), salivary duct carcinoma (SDC), adenoid cystic carcinoma (AdCC), acinic cell carcinoma (AcCC), adenocarcinoma NOS (ACNOS), carcinoma ex pleomorphic adenoma (CAexPA), and squamous cell carcinoma (SqCC), respectively. The average cumulative EGFR scores were 82, 91, 80, 1, 52, 93, and 185 for MEC, SDC, AdCC, AcCC, ACNOS, CAexPA, and SqCC, respectively. CONCLUSIONS: EGFR positive scores and cumulative EGFR scores in SGCs varied among the various histological types, and even in the same histological type. These scores may predict the clinical outcome of SGC treated with EGFR-targeting therapies, such as head and neck photoimmunotherapy, and need to be evaluated in future studies.


Subject(s)
Adenoma, Pleomorphic , Carcinoma, Adenoid Cystic , Carcinoma, Mucoepidermoid , ErbB Receptors , Salivary Gland Neoplasms , Humans , ErbB Receptors/metabolism , Salivary Gland Neoplasms/pathology , Salivary Gland Neoplasms/metabolism , Male , Female , Middle Aged , Carcinoma, Mucoepidermoid/pathology , Carcinoma, Mucoepidermoid/metabolism , Retrospective Studies , Aged , Carcinoma, Adenoid Cystic/metabolism , Carcinoma, Adenoid Cystic/pathology , Adenoma, Pleomorphic/pathology , Adenoma, Pleomorphic/metabolism , Adult , Immunohistochemistry , Aged, 80 and over , Carcinoma, Squamous Cell/pathology , Carcinoma, Squamous Cell/metabolism , Carcinoma, Squamous Cell/surgery , Young Adult , Carcinoma, Acinar Cell/pathology , Carcinoma, Acinar Cell/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL